Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A retrospective study of citalopram in adolescents with depression
Autore:
Bostic, JQ; Prince, J; Brown, K; Place, S;
Indirizzi:
Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Child Psychiat,WACC 725, Boston, MA 02114 USA Harvard Univ Boston MA USA 02114 Psychiat,WACC 725, Boston, MA 02114 USA Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Hanover, NH 03756 USA Dartmouth Coll Hanover NH USA 03756 tmouth Med Sch, Hanover, NH 03756 USA CLM Behav Hlth, Salem, NH USA CLM Behav Hlth Salem NH USACLM Behav Hlth, Salem, NH USA
Titolo Testata:
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY
fascicolo: 2, volume: 11, anno: 2001,
pagine: 159 - 166
SICI:
1044-5463(200122)11:2<159:ARSOCI>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
JUVENILE MOOD DISORDERS; MAJOR DEPRESSION; OPEN-LABEL; FLUOXETINE TREATMENT; OPEN TRIAL; CHILDREN; SERTRALINE; MULTICENTER; PAROXETINE; EFFICACY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
35
Recensione:
Indirizzi per estratti:
Indirizzo: Bostic, JQ Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Child Psychiat,WACC 725, 15 Parkman St, Boston, MA 02114 USA Harvard Univ 15 Parkman St Boston MA USA 02114 on, MA 02114 USA
Citazione:
J.Q. Bostic et al., "A retrospective study of citalopram in adolescents with depression", J CH AD PSY, 11(2), 2001, pp. 159-166

Abstract

Recent evidence suggests that the selective serotonin reuptake inhibitors are safe and efficacious in treating juveniles with depression. However, citalopram has not been reported in adolescents with depression. This study assessed the effectiveness and tolerability of citalopram in all adolescentswith depressive disorders treated naturalistically in a community mental health center during a 1-year interval. Medical charts were retrospectively reviewed for 21 adolescents treated with citalopram for major depression (n= 14), bipolar depression (n = 4), or dysthymia (n = 3). An independent rater compared last visit to baseline depression using the Clinical Global Impression (CGI) Severity and Improvement scales. Adolescents received citalopram for an average of 128.5 +/- 84 days at a final average dose of 26.5 +/- 13.1 mg/day. Sixteen of these 21 adolescents (76%) exhibited much to verymuch improvement as measured by the CGI, and severity of depression diminished significantly (z = 3.007, p <0.0026). Mild side effects, including headaches, dizziness, nausea, sedation, agitation, and sweating were reported by 7 (33%) of the patients. These data suggest that citalopram may be effective, safe, and well tolerated in the treatment of adolescents with depressive disorders and that controlled trials are warranted in this population.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 06:58:03